Eyepoint Pharmaceuticals Stock Cash And Equivalents
| EYPT Stock | USD 10.89 0.83 8.25% |
Eyepoint Pharmaceuticals' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Eyepoint Stock price.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Eyepoint Pharmaceuticals Company Cash And Equivalents Analysis
Eyepoint Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Eyepoint Pharmaceuticals Cash And Equivalents | 171.17 M |
Most of Eyepoint Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyepoint Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Eyepoint Pharmaceuticals has 171.17 M in Cash And Equivalents. This is 79.15% lower than that of the Pharmaceuticals sector and 61.72% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 93.67% higher than that of the company.
Eyepoint Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.Eyepoint Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Eyepoint Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (2.62) % | ||||
| Operating Margin | (2.00) % | ||||
| Current Valuation | 374.05 M | ||||
| Shares Outstanding | 68.81 M | ||||
| Shares Owned By Insiders | 3.50 % | ||||
| Shares Owned By Institutions | 96.50 % | ||||
| Number Of Shares Shorted | 6.72 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 12.37 X | ||||
| Revenue | 43.27 M | ||||
| Gross Profit | (105.66 M) | ||||
| EBITDA | (129.23 M) | ||||
| Net Income | (130.87 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 21.86 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 4.34 X | ||||
| Cash Flow From Operations | (126.23 M) | ||||
| Short Ratio | 8.27 X | ||||
| Earnings Per Share | (2.42) X | ||||
| Target Price | 31.69 | ||||
| Number Of Employees | 165 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 693.32 M | ||||
| Total Asset | 418.46 M | ||||
| Retained Earnings | (873.02 M) | ||||
| Working Capital | 334.26 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
| Net Asset | 418.46 M |
About Eyepoint Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.